Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Saniona

10.48 SEK-1.60 %11.9, 14.57
Less than 1K followers

SANION

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor views
Compare
-1.60 %
-24.50 %
-17.48 %
-32.91 %
-50.57 %
-11.49 %
+80.55 %
-19.36 %
+167.60 %

Saniona is a biotechnology company focused on developing treatments for neurological and psychiatric diseases. The company is researching new therapies that can improve patient outcomes and quality of life. The company operates globally with a primary presence in Europe and North America. Saniona was founded in 2011 and is headquartered in Denmark.

Read more
Market cap
1.45B SEK
Turnover
1.62M SEK
Revenue
434.4M
EBIT %
62.39 %
P/E
4.74
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Research
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.11
2026

Interim report Q3'26

25.2
2027

Annual report '26

Press release07.09.2026, 18.01

Redeye: Saniona (Q2 review): With focus into the clinic

Saniona
Press release01.09.2026, 15.20

BioStock: Saniona’s platform has delivered for others – now it delivers for itself

Saniona
Regulatory press release27.08.2026, 08.00

Saniona publishes its interim report for the second quarter of 2026

Saniona

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release20.08.2026, 08.00

Invitation to Saniona Q2 investor call on 27 August 2026

Saniona
Press release18.08.2026, 09.15

BioStock: Saniona on the equity and milestone upside in the AstronauTx deal

Saniona
Regulatory press release10.08.2026, 08.00

AstronauTx exercises option from Saniona to acquire worldwide rights to neurological disease program under research collaboration

Saniona
Press release23.06.2026, 09.44

Redeye: Saniona: Our take on the SAN2668 R&D day

Saniona
Press release11.06.2026, 09.10

BioStock: Three shots on goal: Saniona prepares to enter the clinic

Saniona
Press release04.06.2026, 08.00

Saniona to Host Virtual R&D Day Focusing on SAN2668 for Severe Pediatric Epilepsies

Saniona
Press release28.05.2026, 18.36

Redeye: Saniona (Q1 Review): Setting up for the long run

Saniona
Regulatory press release27.05.2026, 17.15

Bulletin from the Saniona AB annual shareholders’ meeting on May 27, 2026

Saniona
Regulatory press release26.05.2026, 08.00

Saniona publishes its interim report for the first quarter of 2026

Saniona
Press release20.05.2026, 08.00

Invitation to Saniona Q1 investor call on 26 May 2026

Saniona
Regulatory press release30.04.2026, 13.05

Saniona publishes its Annual Report for 2025

Saniona
Regulatory press release24.04.2026, 17.35

Notice of Saniona AB annual shareholders’ meeting

Saniona
Saniona, Investor Day, Stockholm Corporate Finance Life Science Seminarium 2026
Webcast18.03.2026, 11.30

Saniona, Investor Day, Stockholm Corporate Finance Life Science Seminarium 2026

Saniona
Press release12.03.2026, 14.02

BioStock: Saniona enters clinical execution phase following transformational year

Saniona
Press release12.03.2026, 08.00

Meet Saniona at several conferences during the spring

Saniona
Press release03.03.2026, 10.47

Redeye: Saniona (Q4 review): Moving forward nicely

Saniona
Regulatory press release26.02.2026, 08.00

Saniona publishes its year-end report for 2025

Saniona